[1] |
LIANG Shuang, XIE Yuanliang, FENG Chao, LU Qinchen, TAO Yuting, LV Yuqi, LI Tianyu, WANG Qiuyan, TANG Shaomei.
Analyzing the impact of lncRNA MBNL1-AS1 on the molecular characteristics of Basal subtype muscle-invasive bladder cancer based on omics technologies
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 21-29.
|
[2] |
LI Lei, LIU Xiaodan, ZHOU Kaixiang, HE Linjie, ZHANG Jian, CHEN Qiang, MENG Han, FENG Huan, ZHANG Wenming, LU Jun, ZHOU Feng, CUI Hongzun, NIU Wancheng, ZHANG Zhaohui.
Effects of ischemia postconditioning on mitochondrial function in rats and its protective mechanisms in hepatic ischemia-reperfusion injury
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 48-54.
|
[3] |
JIANG Lu, ZHANG Zhidong, WU Jianjun, LIU Lu, SHANG Longjian, WEI Xingmin .
Changing trends in the disease burden of liver cancer in China and the United States from 1990 to 2021 and its predictions
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 55-60.
|
[4] |
WANG Haodi, DENG Zhengming, WANG Gang, JIANG Zhiwei.
Disease burden in colorectal cancer attributed to fasting hyperglycemia in china from 1990 to 2021 and projections of future trends
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 61-67.
|
[5] |
CAO Le, MA Minmin, LI Wenmin, SHUI Mingming, JIANG Cheng.
Trend of mortality and disease burden of gastric cancer in China,2004—2021
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 68-73.
|
[6] |
CHEN Xiaodan, ZHOU Shu, LYU Yanru, XU Zhiyong, LAN Haiyan, LU Shui, GAO Shan, SHU Liuyang, LIN Siyang, HAO Yanrong, XIE Yanyan.
Study on the initial titration dose and genetic polymorphism of oxycodone hydrochloride prolonged-release tablets in the treatment of severe cancer pain
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 74-80.
|
[7] |
JIA Yingguo, LUO Pengfei, MA Wei, DONG Jinmin, JIAO Dahai.
Development of cancer-specific survival prediction model and risk stratification for patients aged ≥55 years with N1b stage papillary thyroid carcinoma based on the SEER database
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 95-102.
|
[8] |
YANG Jun, KANG Wei, ZHONG Wuning, ZHAO Xin.
Predictive value of radiomics model based on cone-beam breast CT images for pathological complete response of neoadjuvant therapy in breast cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 103-108.
|
[9] |
ZHANG Yuanfen, LONG Ying, YAO Desheng.
Relationship between perineural invasion,clinical pathological characteristics of cervical cancer and its effects on prognosis
[J]. Chinese Journal of Oncology Prevention and Treatment, 2025, 17(1): 109-114.
|
[10] |
GUO Zhiyu, CAO Tianyu, WANG Weidong, GUO Xingxian, MA Wanqi, LU Yuanyuan, ZHAO Xiaodi, JI Gang.
Correlation between blood lipid levels and survival prognosis of gastric cancer patients under operation: A retrospective cohort study
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 687-693.
|
[11] |
XUAN Wenzhen, GONG Jianmin, LI Na.
Incidence,mortality,and disease burden of cervical cancer in China,1990—2021: trends over the past 30 years and future prediction
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 694-700.
|
[12] |
LU Tingting, SHI Lijun, LIU Yingzhao, LIANG Huiting, WANG Qi.
Down⁃regulation of α2⁃macroglobulin expression activates TGF⁃β/SMADs signaling pathway to induce cisplatin resistance in ovarian cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 707-714.
|
[13] |
WANG Xingchen, LIAO Dawen, LI Jiaying, SUN Xiacheng, BI Qian, Huang Qichao, HUANG Jiangtao.
Comparative analysis of molecular characteristics of constitutive activation of NRAS and CTNNB1 in liver cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 577-585.
|
[14] |
DONG Junling, YANG Hui, LI Na.
Trend of the incidence of gastric cancer in China,1992—2021
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 593-597.
|
[15] |
ZHAO Wensi, KE Shaobo, CHEN Jiamei, WU Yong, ZHANG Caiyutian, CHEN Yongshun.
Efficacy and safety of Fruquintinib combined with immune checkpoint inhibitors in later-line treatment of patients with microsatellite stable metastatic colorectal cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(5): 598-605.
|